Clinical Trials

50 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT07235293 2026-04-09

A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

90 enrolled

Colorectal Neoplasms

NCT07515820 2026-04-07

SHR-3821 in Advanced Colorectal Cancer: an Exploratory Study

12 enrolled

Colorectal Neoplasms

NCT07136077 2026-04-06

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

20 enrolled

Colorectal Neoplasms, Neoplasm, Residual

NCT07510932 2026-04-06

FIRST-K

88 enrolled

Colonic Neoplasms

NCT07502014 2026-03-30

A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer

60 enrolled

Colorectal Neoplasms

NCT07011576 2026-03-18

FRUITFUL

60 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT06992258 2026-03-17

FRUITION

120 enrolled

Phase 2 Active not recruiting

Colorectal Neoplasms

NCT06356597 2026-02-24

Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial

33 enrolled

Colorectal Neoplasms

NCT07392346 2026-02-11

Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer

68 enrolled

Gastric Cancer Adenocarcinoma Metastatic

NCT05954429 2026-01-22

A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study

50 enrolled

Colorectal Neoplasms

NCT07353268 2026-01-20

Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy.

76 enrolled

Colorectal Neoplasms

NCT06856837 2025-12-12

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

140 enrolled

Colorectal Neoplasms

NCT07261709 2025-12-03

Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial

236 enrolled

Colorectal Neoplasms

NCT07229872 2025-11-17

A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above Treatment

18 enrolled

Colorectal Neoplasms

NCT07130903 2025-11-10

Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer

102 enrolled

Phase 2 Active not recruiting

Metastatic Colorectal Adenocarcinoma

NCT05177068 2025-10-02

Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer

42 enrolled

Stomach Neoplasms

NCT07170982 2025-09-12

Fruquintinib Combined With Standard Chemotherapy Versus Standard Chemotherapy as First-line Treatment for Advanced pMMR Endometrial Cancer

128 enrolled

Gynecologic

Endometrial Neoplasms

NCT07150403 2025-09-08

Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

74 enrolled

Colorectal Neoplasms

NCT06356584 2025-06-26

Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases

62 enrolled

Colorectal Neoplasms

NCT05771181 2025-06-12

Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients

25 enrolled

Colorectal Neoplasms

NCT07003022 2025-06-04

Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC

40 enrolled

Colonic Neoplasms

NCT05941325 2025-05-18

A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma

20 enrolled

Sarcoma

NCT06973421 2025-05-15

Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Cancer